Free shipping on all orders over $ 500

Padsevonil

Cat. No. M21473
Padsevonil Structure
Synonym:

UCB-0942

Size Price Availability
5mg USD 515  USD515 1-2 Weeks
10mg USD 755  USD755 1-2 Weeks
25mg USD 1460  USD1460 1-2 Weeks
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Padsevonil (UCB0942) is the first effective antiepileptic agent. Padsevonil can be used in the study of epilepsy.

Chemical Information
Molecular Weight 432.8
Formula C14H14ClF5N4O2S
CAS Number 1294000-61-5
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Michael Rademacher, et al. Epilepsia Open. Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: Results from two double-blind, randomized, placebo-controlled trials

[2] Samia Elkommos, et al. Expert Opin Pharmacother. Current and future pharmacotherapy options for drug-resistant epilepsy

[3] Pierandrea Muglia, et al. Brain Commun. Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach

[4] Isabelle Niespodziany, et al. Epilepsia. Functional characterization of the antiepileptic drug candidate, padsevonil, on GABAA receptors

[5] Marco Mula. Expert Opin Emerg Drugs. Emerging drugs for focal epilepsy

Related Products
Izeltabart

Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models.

Cofetuzumab

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7.

Crizanlizumab

Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs).

M3554 (anti-GD2 ADC)

M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity.

OGT2115

OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Padsevonil, UCB-0942 supplier, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.